Immune Disease Clinical Trial
Official title:
Effect of Monoclonal Anti-cd303 on the Inhibition of Type I Interferon Secretion in the Peripheral Blood of Patients With Autoimmune Diseases
The pathogenic role of type I interferons (IFNs) in the development of different autoimmune
diseases has been extensively described in the literature. Since plasmacytoid dendritic cells
(pDCs) are the main source of type I IFNs, there is evidence of the involvement of pDCs in
autoimmune diseases. The CD303 surface protein (also called BDCA-2) is specifically expressed
by the pDCs.
The hypothesis leading to the realization of this study is to observe, in vitro, an
inhibition of the secretion of the type I IFNs by pDCs in the peripheral blood in patients
with autoimmune disease, thanks to the action of the anti-CD303 antibody Developed by the LFB
Group, which could reduce the inflammatory response and improve patients with autoimmune
disease
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03994302 -
Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
|